Cargando…

Tackling Drug Resistance in EGFR Exon 20 Insertion Mutant Lung Cancer

Insertion mutations in exon 20 (Ex20ins) of the epidermal growth factor receptor (EGFR) gene are the largest class of EGFR mutations in non-small cell lung cancer (NSCLC) for which there are currently no approved targeted therapies. NSCLC patients with these mutations do not respond to clinically ap...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pacini, Laura, Jenks, Andrew D, Vyse, Simon, Wilding, Christopher P, Arthur, Amani, Huang, Paul H
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7955704/ https://www.ncbi.nlm.nih.gov/pubmed/33727854 http://dx.doi.org/10.2147/PGPM.S242045

Ejemplares similares

Targeting EGFR exon 20 insertion mutations in non-small cell lung cancer
por: Vyse, Simon, et al.
Publicado: (2019)

EGFR Exon 20 Insertion Mutations in Sinonasal Squamous Cell Carcinoma
por: Pacini, Laura, et al.
Publicado: (2022)

Amivantamab and Mobocertinib in Exon 20 insertions EGFR Mutant Lung Cancer, Challenge To The Current Guidelines
por: Olivier, Timothée, et al.
Publicado: (2022)

Osimertinib as treatment for EGFR exon 20 insertion-positive lung adenocarcinoma
por: Murano, Chihiro, et al.
Publicado: (2019)

Not All EGFR Exon 20 Insertions Are Created Equal
por: Lin, Yen-Ting, et al.
Publicado: (2020)

EGFR exon 20 insertion mutations in non-small cell lung cancer
por: Wang, Fenfang, et al.
Publicado: (2020)

EGFR Testing Patterns and Detection of EGFR Exon 20 Insertions in the United States
por: Lin, Huamao M., et al.
Publicado: (2022)

EGFR-D770>GY and Other Rare EGFR Exon 20 Insertion Mutations with a G770 Equivalence Are Sensitive to Dacomitinib or Afatinib and Responsive to EGFR Exon 20 Insertion Mutant-Active Inhibitors in Preclinical Models and Clinical Scenarios
por: Kobayashi, Ikei S., et al.
Publicado: (2021)

Structural Basis for the Functional Changes by EGFR Exon 20 Insertion Mutations
por: Tamirat, Mahlet Z., et al.
Publicado: (2021)

EGFR exon 20 insertion mutations and response to osimertinib in non-small-cell lung cancer
por: Fang, Wenfeng, et al.
Publicado: (2019)

Clinicopathologic and molecular characteristics of Chinese lung adenocarcinoma patients with EGFR exon 20 insertion mutations
por: Wang, Lifeng, et al.
Publicado: (2022)

Real-world efficacy and safety of mobocertinib in EGFR exon 20 insertion-mutated lung cancer
por: Kian, Waleed, et al.
Publicado: (2022)

Variability of EGFR exon 20 insertions in 24 468 Chinese lung cancer patients and their divergent responses to EGFR inhibitors
por: Qin, YanRu, et al.
Publicado: (2020)

Impact of EGFR amplification on survival of patients with EGFR exon 20 insertion-positive non-small cell lung cancer
por: Gao, Xin, et al.
Publicado: (2020)

Spotlight on Mobocertinib (TAK-788) in NSCLC with EGFR Exon 20 Insertion Mutations
por: Zhang, Shannon S, et al.
Publicado: (2021)

Poor effect of osimertinib on EGFR exon 20 insertion-positive lung adenocarcinoma: A case report
por: Inagaki, Yuji, et al.
Publicado: (2020)

Clinical characteristics of advanced non-small cell lung cancer patients with EGFR exon 20 insertions
por: Morita, Chie, et al.
Publicado: (2021)

A lung adenocarcinoma patient with co-mutations of MET and EGFR exon20 insertion responded to crizotinib
por: Chen, Yan, et al.
Publicado: (2022)

Advances in the management of non-small-cell lung cancer harbouring EGFR exon 20 insertion mutations
por: Low, Jia Li, et al.
Publicado: (2023)

Clinical Outcomes of EGFR Exon 20 Insertion Mutations in Advanced Non-small Cell Lung Cancer in Korea
por: Byeon, Seonggyu, et al.
Publicado: (2019)

Spotlight on Amivantamab (JNJ-61186372) for EGFR Exon 20 Insertions Positive Non-Small Cell Lung Cancer
por: Brazel, Danielle, et al.
Publicado: (2021)

EGFR exon 20 insertion mutations in advanced non-small-cell lung cancer: current status and perspectives
por: Hou, Jiabao, et al.
Publicado: (2022)

Epidemiological characteristics and therapeutic advances of EGFR exon 20 insertion mutations in non‐small cell lung cancer
por: Pan, Binyang, et al.
Publicado: (2023)

Sunvozertinib, a Selective EGFR Inhibitor for Previously Treated Non–Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations
por: Wang, Mengzhao, et al.
Publicado: (2022)

Real-World Response and Outcomes in Patients With NSCLC With EGFR Exon 20 Insertion Mutations
por: Ou, Sai-Hong Ignatius, et al.
Publicado: (2023)

EGFR Exon 20 Insertion in Metastatic Non-Small-Cell Lung Cancer: Survival and Clinical Efficacy of EGFR Tyrosine-Kinase Inhibitor and Chemotherapy
por: Chelabi, Samy, et al.
Publicado: (2021)

Emerging therapies for non-small cell lung cancer harboring EGFR exon 20 insertion mutations: narrative review
por: Watanabe, Naohiro, et al.
Publicado: (2022)

Non-small Cell Lung Cancer with EGFR or HER2 Exon 20 Insertion Mutations: Diagnosis and Treatment Options
por: Brazel, Danielle, et al.
Publicado: (2022)

Response to Afatinib in a Patient with NSCLC Harboring Novel EGFR Exon 20 Insertion Mutations
por: Lin, Ling, et al.
Publicado: (2020)

Activity of tarloxotinib‐E in cells with EGFR exon‐20 insertion mutations and mechanisms of acquired resistance
por: Nishino, Masaya, et al.
Publicado: (2021)

Preclinical Characterization of Mobocertinib Highlights the Putative Therapeutic Window of This Novel EGFR Inhibitor to EGFR Exon 20 Insertion Mutations
por: Vasconcelos, Pedro E.N.S., et al.
Publicado: (2020)

The EGFR C797S Mutation Confers Resistance to a Novel EGFR Inhibitor CLN-081 to EGFR Exon 20 Insertion Mutations
por: Kagawa, Yosuke, et al.
Publicado: (2023)

Targeting HER2 Exon 20 Insertion–Mutant Lung Adenocarcinoma with a Novel Tyrosine Kinase Inhibitor Mobocertinib
por: Han, Han, et al.
Publicado: (2021)

Case Report: Two Patients With EGFR Exon 20 Insertion Mutanted Non-Small Cell Lung Cancer Precision Treatment Using Patient-Derived Xenografts in Zebrafish Embryos
por: Wang, Qian, et al.
Publicado: (2022)

Sensitivity to Immune Checkpoint Blockade in Advanced Non-Small Cell Lung Cancer Patients with EGFR Exon 20 Insertion Mutations
por: Metro, Giulio, et al.
Publicado: (2021)

Real-world clinical treatment outcomes in Chinese non-small cell lung cancer with EGFR exon 20 insertion mutations
por: Shi, Chao, et al.
Publicado: (2022)

Poor Efficacy of Immune Checkpoint Inhibitors Plus Chemotherapy in Lung Cancer Patients with EGFR/ERBB2 Exon 20 Insertion
por: Zheng, Yue, et al.
Publicado: (2023)

Human Papillomavirus Infection and EGFR Exon 20 Insertions in Sinonasal Inverted Papilloma and Squamous Cell Carcinoma
por: Hirakawa, Hitoshi, et al.
Publicado: (2023)

Phase 1b trial of anti-EGFR antibody JMT101 and Osimertinib in EGFR exon 20 insertion-positive non-small-cell lung cancer
por: Zhao, Shen, et al.
Publicado: (2023)

Molecular determinants of drug-specific sensitivity for epidermal growth factor receptor (EGFR) exon 19 and 20 mutants in non-small cell lung cancer
por: Tsigelny, Igor F., et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_1h9b5th1nqb6jema2ikclddc7l